Pacira Biosciences Q1 2026: Revenue and EPS Beat Estimates as Pipeline Catalysts Loom
Pacira BioSciences (NASDAQ:PCRX) reported first-quarter 2026 results on April 30, delivering a top- and bottom-line beat against analyst expectations. The company posted total revenue of $177.4 million and non-GAAP earnings per share of $0.60, compared to the consensus estimate of $176.8 million in revenue and $0.5746 in EPS. While the beats were modest, the underlying operational trends and a reaffirmed full-year outlook are providing a floor for the stock, which has seen a slight uptick in after-hours trading.
Revenue and Earnings Performance
The 5 percent year-over-year revenue growth to $177.4 million was driven by solid volume gains across all three commercial-stage products. The company’s flagship non-opioid pain therapy, EXPAREL, delivered $143.3 million in net product sales, a 5 percent increase from the prior-year quarter, with volume growth of 7 percent partially offset by vial mix shifts and discounts tied to a new group purchasing organization partnership.
The other two commercial assets also showed strong momentum:
- ZILRETTA net product sales rose 15 percent year-over-year to $26.8 million.
- iovera net product sales jumped 21 percent to $6.2 million.
On the bottom line, GAAP net income came in at $2.9 million, or $0.07 per share, down from $4.8 million a year earlier due to higher operating expenses. However, on an adjusted basis, non-GAAP net income was $24.5 million, or $0.60 per share—a slight decline from $30.0 million ($0.65 per share) in Q1 2025. Adjusted EBITDA was $40.2 million for the quarter.
Key Pipeline and Business Developments
Beyond the quarterly numbers, management highlighted several catalysts that investors are watching closely.
The most notable near-term event is the enrollment completion for the Phase 3 registrational study of ZILRETTA for osteoarthritis pain of the shoulder. Topline results are expected by year-end 2026. If successful, ZILRETTA could become the first product with an on-label indication for shoulder OA pain, opening a significant new market opportunity.
Additionally, the company is advancing its gene therapy candidate PCRX-201 for knee OA. Data from Part A of the Phase 2 ASCEND study is expected later this year, following promising Phase 1 results that showed sustained improvements in pain and function out to two years.
Pacira also presented multiple real-world studies at medical meetings during the quarter, reinforcing the economic value of EXPAREL in total hip and knee arthroplasty procedures.
Financial Position and Capital Allocation
Pacira ended the quarter with $202.2 million in cash, cash equivalents, and short-term investments. The company continues to execute on its share repurchase program, buying back 2.2 million shares at an average price of $22.28 during Q1 for $50 million. As of March 31, $100 million remained under the current authorization, which expires at year-end 2026.
Outlook and Guidance
Pacira reaffirmed its full-year 2026 guidance, which calls for:
- Total revenue: $745 million to $770 million
- EXPAREL net product sales: $600 million to $620 million
- Non-GAAP gross margin: 77 percent to 79 percent
- Non-GAAP R&D expense: $105 million to $115 million
- Non-GAAP SG&A expense: $320 million to $340 million
For context, analysts are currently estimating full-year 2026 total revenue of approximately $775.7 million and Q2 2026 revenue of $193.9 million. The company’s forecasts sit slightly below the consensus top-line number for the full year, which may explain the measured market reaction despite the quarterly beat.
Market Reaction
The stock has appreciated roughly 12 percent over the past month and roughly 7 percent over the past two weeks, suggesting anticipation of the quarterly results. The after-market move is essentially flat (+0.16%), indicating that the slight beat on both revenue and EPS was largely priced in. Investors appear to be focusing on the upcoming pipeline readouts—ZILRETTA shoulder data and the PCRX-201 Phase 2 data—as the primary catalysts for further upside.
For more historical earnings data and future projections, visit the PACIRA BIOSCIENCES INC earnings page and analyst forecasts page.